Alvotech files EU application for Eylea HD biosimilar AVT29
ALVO•Alvotech filed a European Medicines Agency application for AVT29, a proposed biosimilar to Eylea 8 mg, as a line extension to Mynzepli’s existing European marketing authorization.
1. EU application filed
Alvotech filed the application for AVT29 as a line extension to the existing European marketing authorization for Mynzepli, its Eylea 2 mg biosimilar. Partner Advanz Pharma will handle registration and commercialization in Europe under the companies’ agreement.
